Amgen Inc. vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

A Tale of Two Biopharma Giants: Amgen Inc. vs Supernus Pharmaceuticals, Inc.

In the competitive landscape of biopharmaceuticals, Amgen Inc. and Supernus Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit performance over the past decade. From 2014 to 2023, Amgen's gross profit has consistently soared, peaking at nearly $20 billion in 2022, reflecting a robust growth of approximately 27% from its 2014 figures. This growth underscores Amgen's strategic prowess in the industry.

Conversely, Supernus Pharmaceuticals, Inc., while significantly smaller, has demonstrated impressive growth dynamics. Starting with a gross profit of around $116 million in 2014, Supernus has achieved a remarkable increase of nearly 400% by 2022, reaching approximately $580 million. This growth trajectory highlights Supernus's potential and resilience in a highly competitive market.

These insights reveal the diverse strategies and market positions of these two companies, offering a fascinating glimpse into the evolving biopharma sector.